MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41408-021-00580-7

Медицинская библиотека · Blood cancer journal · 2021

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.

Rognvaldsson Saemundur, Eythorsson Elias, Thorsteinsdottir Sigrun, Vidarsson Brynjar, Onundarson Pall Torfi, Agnarsson Bjarni A, Sigurdardottir Margret, Thorsteinsdóttir Ingunn, Olafsson Isleifur, Runolfsdottir Hrafnhildur L, Helgason Dadi, Emilsdottir Arna R, Agustsson Arnar S, Bjornsson Aron H, Kristjansdottir Gudrun, Thordardottir Asdis Rosa, Indridason Olafur Skuli, Jonsson Asbjorn, Gislason Gauti Kjartan, Olafsson Andri, Steingrimsdottir Hlif, Kampanis Petros, Hultcrantz Malin, Durie Brian G M, Harding Stephen, Landgren Ola, Palsson Runolfur, Love Thorvarður Jon, Kristinsson Sigurdur Yngvi

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81-1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52-1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.

Для цитирования: Rognvaldsson Saemundur, Eythorsson Elias, Thorsteinsdottir Sigrun, Vidarsson Brynjar, Onundarson Pall Torfi, Agnarsson Bjarni A, Sigurdardottir Margret, Thorsteinsdóttir Ingunn, Olafsson Isleifur, Runolfsdottir Hrafnhildur L, Helgason Dadi, Emilsdottir Arna R, Agustsson Arnar S, Bjornsson Aron H, Kristjansdottir Gudrun, Thordardottir Asdis Rosa, Indridason Olafur Skuli, Jonsson Asbjorn, Gislason Gauti Kjartan, Olafsson Andri, Steingrimsdottir Hlif, Kampanis Petros, Hultcrantz Malin, Durie Brian G M, Harding Stephen, Landgren Ola, Palsson Runolfur, Love Thorvarður Jon, Kristinsson Sigurdur Yngvi. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.. Blood cancer journal. 2021. DOI: 10.1038/s41408-021-00580-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.